BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38006528)

  • 1. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):899-900. PubMed ID: 38006528
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Supraclavicular Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma.
    Park SY; Lee J; Jeon YJ; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM
    Ann Surg Oncol; 2024 Mar; 31(3):1583-1584. PubMed ID: 38190057
    [No Abstract]   [Full Text] [Related]  

  • 3. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma.
    Xie C; Hu Y; Han L; Fu J; Vardhanabhuti V; Yang H
    Ann Surg Oncol; 2022 Dec; 29(13):8127-8128. PubMed ID: 35933539
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Preservation of the Thoracic Duct is Feasible for Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy After Neoadjuvant Chemoradiotherapy.
    Oshikiri T; Numasaki H; Oguma J; Toh Y; Watanabe M; Muto M; Kakeji Y; Doki Y
    Ann Surg Oncol; 2023 May; 30(5):2699-2700. PubMed ID: 36629993
    [No Abstract]   [Full Text] [Related]  

  • 6. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
    J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
    Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
    Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
    Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Pathological Staging in Esophageal Squamous Cell Carcinoma.
    Lam AK
    Methods Mol Biol; 2020; 2129():19-31. PubMed ID: 32056167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Ann Surg Oncol; 2024 Jan; 31(1):241-242. PubMed ID: 37838649
    [No Abstract]   [Full Text] [Related]  

  • 15. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-of-the-art chemoradiation is no substitution for trimodality approach in the treatment of locally advanced thoracic esophageal squamous cell carcinoma.
    Yang HY; Liao KS; Lee CY; Kam KH
    Asian J Surg; 2023 Aug; 46(8):3383-3384. PubMed ID: 36990809
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5895-5896. PubMed ID: 37266806
    [No Abstract]   [Full Text] [Related]  

  • 18. Minimally Invasive Esophagectomy with Thoracic Duct Resection Post Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus-Impact on Lymph Node Yield and Hemodynamic Parameters.
    Anand S; Kalayarasan R; Chandrasekar S; Gnanasekaran S; Pottakkat B
    J Gastrointest Cancer; 2019 Jun; 50(2):230-235. PubMed ID: 29344808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Borderline Resectable Esophageal Squamous Cell Carcinoma.
    Hosogi H; Yoshida S; Sakaguchi M; Kanaya S
    J Gastrointest Surg; 2023 Dec; 27(12):3040-3042. PubMed ID: 37919516
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Using Efficacy Index to Clarify the Clinical Value of Each Lymph Node Station for Esophageal Squamous Cell Carcinoma.
    Nie X; Li K; Peng L; Leng X
    Ann Surg Oncol; 2023 Sep; 30(9):5866-5867. PubMed ID: 37322279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.